Citius Oncology (CTOR) EPS (Weighted Average and Diluted) (2023 - 2026)

Citius Oncology's EPS (Weighted Average and Diluted) history runs 4 years deep, the most recent figure standing at -$0.27 for Q1 2026.

• In Q1 2026, EPS (Weighted Average and Diluted) fell 145.45% year-over-year to -$0.27; the TTM figure through Mar 2026 stood at -$0.47 (down 38.24% YoY), while the FY2025 annual figure was -$0.34, down 9.68% from the prior year.
• EPS (Weighted Average and Diluted) was -$0.27 for Q1 2026 at Citius Oncology, down from -$0.06 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.07 in Q1 2023 to a low of -$0.27 in Q1 2026.
• Historically, EPS (Weighted Average and Diluted) has averaged -$0.06 across 4 years, with a median of -$0.07 in 2023.
• The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) sank 200.0% in 2024, then soared 33.33% in 2025.
• A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.07 in 2023, then dropped by 28.57% to -$0.09 in 2024, then surged by 33.33% to -$0.06 in 2025, then tumbled by 350.0% to -$0.27 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.27 (Q1 2026), -$0.06 (Q4 2025), and -$0.06 (Q3 2025), per Business Quant data.